Balyasny Asset Management L.P. Purchases Shares of 60,317 Chimerix, Inc. (NASDAQ:CMRX)

Balyasny Asset Management L.P. acquired a new stake in Chimerix, Inc. (NASDAQ:CMRX) during the fourth quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor acquired 60,317 shares of the biopharmaceutical company’s stock, valued at approximately $210,000. Balyasny Asset Management L.P. owned 0.07% of Chimerix as of its most recent filing with the Securities and Exchange Commission (SEC).

Several other institutional investors have also recently modified their holdings of the company. Bender Robert & Associates purchased a new stake in Chimerix in the fourth quarter valued at $37,000. Susquehanna Fundamental Investments LLC purchased a new position in shares of Chimerix during the 4th quarter valued at about $59,000. Jane Street Group LLC acquired a new position in shares of Chimerix in the 4th quarter valued at about $62,000. Diadema Partners LP purchased a new stake in shares of Chimerix in the fourth quarter worth about $101,000. Finally, Stoneridge Investment Partners LLC grew its holdings in Chimerix by 22.5% during the fourth quarter. Stoneridge Investment Partners LLC now owns 44,305 shares of the biopharmaceutical company’s stock worth $154,000 after acquiring an additional 8,134 shares during the period. 45.42% of the stock is currently owned by hedge funds and other institutional investors.

Chimerix Price Performance

Shares of NASDAQ:CMRX opened at $8.54 on Monday. Chimerix, Inc. has a 1 year low of $0.75 and a 1 year high of $8.55. The firm has a market capitalization of $801.09 million, a PE ratio of -9.09 and a beta of -0.17. The business’s 50 day moving average price is $8.52 and its 200-day moving average price is $5.09.

Chimerix (NASDAQ:CMRX) last announced its earnings results on Friday, March 21st. The biopharmaceutical company reported ($0.25) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.26) by $0.01. The business had revenue of $0.06 million for the quarter, compared to analyst estimates of $0.31 million. As a group, analysts expect that Chimerix, Inc. will post -0.99 earnings per share for the current year.

Analyst Upgrades and Downgrades

CMRX has been the subject of a number of analyst reports. HC Wainwright restated a “neutral” rating and set a $8.55 price target (down previously from $11.00) on shares of Chimerix in a research report on Wednesday, March 5th. StockNews.com assumed coverage on Chimerix in a research note on Sunday. They issued a “sell” rating for the company. Jefferies Financial Group reaffirmed a “hold” rating and issued a $8.50 price target (down previously from $10.00) on shares of Chimerix in a report on Wednesday, March 5th. Finally, Wedbush reissued a “neutral” rating and issued a $8.55 price objective (up from $7.00) on shares of Chimerix in a report on Wednesday, March 5th.

Chimerix Profile

Chimerix, Inc, a biopharmaceutical company, develops medicines to improve and extend the lives of patients facing deadly diseases. Its pipeline products include ONC201 a program that is in Phase 3 clinical trial for treating patients with H3 K27M-mutant diffuse glioma, as well as in Phase 2 clinical trial for the treatment of rare neuroendocrine tumors; and ONC206, an imipridone, Dopamine Receptor D2 (DRD2) antagonist, and caseinolytic protease P (ClpP) agonist, which is in Phase 1 clinical trial for adult and pediatric patients with primary central nervous system tumors.